Navigation Links
Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
Date:12/3/2008

GOTHENBURG, Sweden, December 3 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced the signing of a collaborative agreement with The Automation Partnership (TAP) in the UK, manufacturers of advanced automated systems for cell culture, sample management and high throughput screening applications. Under the agreement TAP will co-develop and manufacture the Dynaflow(R)HT System, Cellectricon's next generation high throughput ion channel screening platform. Dynaflow(R)HT will be launched and commercially available in 2009.

Addressing the limitations of current ion channel screening technologies, the Dynaflow(R)HT yields an unmatched level of automated throughput while still delivering unique measurement data quality. The concept and technology has been developed and validated over the last three years by Cellectricon in partnership with AstraZeneca.

"We are excited to partner with TAP who are world-renowned for manufacturing industrial quality automation," says Jonas Ohlsson, CEO at Cellectricon. "To bring this fully automated state-of-the-art high throughput electrophysiology system to the market is a milestone for ion channel screening. The system offers unmatched throughput, cost per data point and reliability/predictability."

"The Automation Partnership (TAP) are very pleased to have the opportunity to work with Cellectricon in automating their unique high throughput microfluidic screening platform," says Andy Morffew Chief Executive Officer. "We are looking forward to supporting this system with a wide range of excellent technical and professional services, designed to ensure customers gain optimum return from their capital investment."

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007, the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

About The Automation Partnership

The Automation Partnership (TAP) is a world leader in the design, development and implementation of advanced automation systems for the life sciences research industry. TAP specializes in automation for cell culture, sample management and advanced screening applications. These range from multi-million pound large-scale drug discovery facilities to standalone bench-top products. TAP also offers custom engineering services to customers requiring unique solutions for complex and challenging research problems.

TAP's customers include the world's top pharmaceutical and biotechnology companies, key service providers and leading research institutions including: Amgen, AstraZeneca, ATCC, GlaxoSmithKline, Loughborough University, Max Planck Institute, Merck, Oxford University, Stem Cell Sciences, UK Biobank and Wyeth.

    Contact Cellectricon:

    Jonas Ohlsson, CEO
    Phone: +46(0)709-73-47-92
    E-mail: jonas.ohlsson@cellectricon.com

    Susanne Fagerlund, VP Marketing & Communications
    Phone: +46(0)31-760-35-15
    Email: susanne.fagerlund@cellectricon.com

    Contact The Automation Partnership:

    Matthew Walker, Head of Communications
    Phone: +44(0)1763-22-72-00
    E-mail: matthew.walker@automationpartnership.com


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
2. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
3. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
4. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
5. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
6. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
7. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
8. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
10. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
11. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):